Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D
Sign Up to like & getrecommendations! Published in 2025 at "Liver International"
DOI: 10.1111/liv.70404
Abstract: Bulevirtide (BLV) is the only approved therapy for chronic hepatitis D (CHD) and compensated liver disease. Daily subcutaneous injection and the need for refrigeration may pose challenges, especially in patients with limited language proficiency. read more here.
Keywords: handling perception; impact handling; hepatitis; language ... See more keywords